Last reviewed · How we verify
Mitozantrone — Competitive Intelligence Brief
phase 2
Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Mitozantrone (Mitozantrone) — US Department of Veterans Affairs.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mitozantrone TARGET | Mitozantrone | US Department of Veterans Affairs | phase 2 | Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mitozantrone CI watch — RSS
- Mitozantrone CI watch — Atom
- Mitozantrone CI watch — JSON
- Mitozantrone alone — RSS
Cite this brief
Drug Landscape (2026). Mitozantrone — Competitive Intelligence Brief. https://druglandscape.com/ci/mitozantrone. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing